The global bone graft substitutes market size was estimated to be USD 3.82 billion in 2023 and is expected to reach at USD 7.53 billion by 2034 with a CAGR of 6.37% during the forecast period 2024-2034. Growing demand for synthetic substitutes, surge in number of product approvals by regulatory authorities, increasing demand for the development of biocompatible bone grafts to minimize adverse reactions in patients, the utilization of synthetic grafts containing Hydroxyapatite (HAp) and Tricalcium Phosphate (TCP) is on the rise, as these materials have demonstrated superior biocompatibility compared to other alternatives, rising supportive regulatory framework, growing adoption of minimally invasive procedures, and increased efforts by market participants to develop new products with enhanced properties are some of the key factors boosting the market growth.
Increased efforts by market participants to develop new products with enhanced properties is predicted to boost the market growth during the forecast period. Bone grafts and substitutes provide numerous benefits and advantages, such as biocompatibility, safety, and osteoconductivity, all of which play a crucial role in the healing and recuperation of fractured bones. For instance, in March 2022, The Osteo-P Synthetic Bone Graft Substitute from Molecular Matrix, Inc. is now available for use in musculoskeletal applications. This product has been developed using HCCP technology, which offers significant benefits in bone regeneration and repair.
By material, allograft was the highest revenue-grossing segment in the global bone graft substitutes market in 2023 owing to its properties, particularly osteoconductivity & immediate structural support, positive patient outcomes with allograft products, and rising introductions of allografts. Additionally, synthetic is predicted to grow at fastest CAGR during the forecast period as these products are associated with lower risks of disease transmission, improved biocompatibility, & are generally better accepted by patients when compared to allografts, increasing prevalence of orthopedic disorders, and growing demand for synthetic orthopedic products. For instance, in February 2023, NuVasive, Inc., a prominent figure in technology innovation, has enhanced its C360 portfolio by broadening the indications for Attrax Putty and Modulus Cervical. Attrax Putty represents the first synthetic bone graft substitute applied in thoracolumbar interbody fusion spacers. This expansion will bring added value to the cervical category, particularly benefiting hospitals and surgeons.
By application, spinal fusion was the highest revenue-grossing segment in the global bone graft substitutes market in 2023 owing to the growing adoption of bone graft materials for procedures like spondylosyndesis, surge in elderly population who are more susceptible to various orthopedic conditions, and rising introduction of new products. For instance, in February 2022, Opus B.A., a brand-new synthetic bioactive bone graft solution from Orthofix Medical Inc., is intended for use in lumbar and cervical spine fusion surgeries. Additionally, dental is predicted to grow at fastest CAGR during the forecast period owing to the surge in adoption of grafts for dental procedures, growing acceptance of dental implant surgical procedures, alongside advanced techniques like bone grafts and bone regeneration, and increasing success rates of dental implants.
By end-user, hospitals was the highest revenue-grossing segment in the global bone graft substitutes market in 2023 owing to a significant number of orthopedic specialists working in hospitals, surge in patient visits in hospitals for a variety of spinal & joint reconstruction surgeries, and growing launch of innovative products. For instance, in May 2023, AlloSource, a U.S.-based allograft provider, has unveiled AlloMend Duo Acellular Dermal Matrix (ADM), a solution designed for soft tissue reconstruction. This product aids surgeons in reshaping soft tissue to offer long-term structural support, making it suitable for use as a bone graft substitute and maintaining biocompatibility within the regenerative tissue matrix. Additionally, specialty clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of orthopedic specialty clinics, rising emphasis on establishing medical facilities, including specialty clinics, to accommodate a larger number of patients, and growing healthcare infrastructure.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in geriatric population, growing incidence of sports injuries & fatal accidents, the presence of well-established healthcare infrastructure, increasing reimbursement policies, and presence of a large number of orthopedic surgeons who perform surgeries involving the use of bone grafts, and rising introduction of advanced products. For instance, in October 2022, LifeNet Health is presenting its advanced allograft biologics for fusion at the North American Spine Society (NASS) 2022 Annual Meeting in Chicago. As a global leader in allograft solutions and processing technology, LifeNet Health will showcase the increasing body of evidence supporting their solutions for thoracic, cervical, and lumbar fusions, which includes products like ViviGen Cellular Bone Matrix, PliaFX Prime moldable demineralized fibers, and VertiGraft structural allografts. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to a substantial patient population with a wide variety of orthopedic conditions, market participants are increasing their investments to extend their reach and presence in the market, and growing approvals by regulatory bodies. For instance, in October 2022, CGBio's material, known as Novosis, has received approvals in South Korea, Mexico, India, and Southeast Asia. It can be described as a recombinant human bone morphogenetic protein-2 bone growth material, which serves as a scaffold for the generation of new bone while offering flexibility in handling and shaping.
HAP
α-TCP
β-TCP
Others
Increased efforts by market participants to develop new products with enhanced properties is predicted to boost the market growth during the forecast period. Bone grafts and substitutes provide numerous benefits and advantages, such as biocompatibility, safety, and osteoconductivity, all of which play a crucial role in the healing and recuperation of fractured bones. For instance, in March 2022, The Osteo-P Synthetic Bone Graft Substitute from Molecular Matrix, Inc. is now available for use in musculoskeletal applications. This product has been developed using HCCP technology, which offers significant benefits in bone regeneration and repair.
By material, allograft was the highest revenue-grossing segment in the global bone graft substitutes market in 2023 owing to its properties, particularly osteoconductivity & immediate structural support, positive patient outcomes with allograft products, and rising introductions of allografts. Additionally, synthetic is predicted to grow at fastest CAGR during the forecast period as these products are associated with lower risks of disease transmission, improved biocompatibility, & are generally better accepted by patients when compared to allografts, increasing prevalence of orthopedic disorders, and growing demand for synthetic orthopedic products. For instance, in February 2023, NuVasive, Inc., a prominent figure in technology innovation, has enhanced its C360 portfolio by broadening the indications for Attrax Putty and Modulus Cervical. Attrax Putty represents the first synthetic bone graft substitute applied in thoracolumbar interbody fusion spacers. This expansion will bring added value to the cervical category, particularly benefiting hospitals and surgeons.
By application, spinal fusion was the highest revenue-grossing segment in the global bone graft substitutes market in 2023 owing to the growing adoption of bone graft materials for procedures like spondylosyndesis, surge in elderly population who are more susceptible to various orthopedic conditions, and rising introduction of new products. For instance, in February 2022, Opus B.A., a brand-new synthetic bioactive bone graft solution from Orthofix Medical Inc., is intended for use in lumbar and cervical spine fusion surgeries. Additionally, dental is predicted to grow at fastest CAGR during the forecast period owing to the surge in adoption of grafts for dental procedures, growing acceptance of dental implant surgical procedures, alongside advanced techniques like bone grafts and bone regeneration, and increasing success rates of dental implants.
By end-user, hospitals was the highest revenue-grossing segment in the global bone graft substitutes market in 2023 owing to a significant number of orthopedic specialists working in hospitals, surge in patient visits in hospitals for a variety of spinal & joint reconstruction surgeries, and growing launch of innovative products. For instance, in May 2023, AlloSource, a U.S.-based allograft provider, has unveiled AlloMend Duo Acellular Dermal Matrix (ADM), a solution designed for soft tissue reconstruction. This product aids surgeons in reshaping soft tissue to offer long-term structural support, making it suitable for use as a bone graft substitute and maintaining biocompatibility within the regenerative tissue matrix. Additionally, specialty clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of orthopedic specialty clinics, rising emphasis on establishing medical facilities, including specialty clinics, to accommodate a larger number of patients, and growing healthcare infrastructure.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in geriatric population, growing incidence of sports injuries & fatal accidents, the presence of well-established healthcare infrastructure, increasing reimbursement policies, and presence of a large number of orthopedic surgeons who perform surgeries involving the use of bone grafts, and rising introduction of advanced products. For instance, in October 2022, LifeNet Health is presenting its advanced allograft biologics for fusion at the North American Spine Society (NASS) 2022 Annual Meeting in Chicago. As a global leader in allograft solutions and processing technology, LifeNet Health will showcase the increasing body of evidence supporting their solutions for thoracic, cervical, and lumbar fusions, which includes products like ViviGen Cellular Bone Matrix, PliaFX Prime moldable demineralized fibers, and VertiGraft structural allografts. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to a substantial patient population with a wide variety of orthopedic conditions, market participants are increasing their investments to extend their reach and presence in the market, and growing approvals by regulatory bodies. For instance, in October 2022, CGBio's material, known as Novosis, has received approvals in South Korea, Mexico, India, and Southeast Asia. It can be described as a recombinant human bone morphogenetic protein-2 bone growth material, which serves as a scaffold for the generation of new bone while offering flexibility in handling and shaping.
Segmentation: Bone Graft Substitutes Market Report 2023 - 2034
Bone Graft Substitutes Market Analysis & Forecast by Material 2023 - 2034 (Revenue USD Bn)
- Allograft
- Demineralized Bone Matrix
- Others
- Synthetic
- Bone Morphogenic Proteins (BMP)
- Polymers
- Composites
- Ceramics
HAP
α-TCP
β-TCP
Others
Bone Graft Substitutes Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Dental
- Joint Reconstruction
- Spinal Fusion
- Craniomaxillofacial
- Long Bone
- Foot & Ankle
Bone Graft Substitutes Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Others
Bone Graft Substitutes Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Bone Graft Substitutes Market: Material Estimates & Trend Analysis
8. Bone Graft Substitutes Market: Application Estimates & Trend Analysis
9. Bone Graft Substitutes Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Bone Graft Substitutes Market
12. Europe Global Bone Graft Substitutes Market
13. Asia Pacific Global Bone Graft Substitutes Market
14. Latin America Global Bone Graft Substitutes Market
15. MEA Global Bone Graft Substitutes Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- AlloSource
- Baxter
- Zimmer Biomet
- Smith + Nephew
- Medtronic
- OST Laboratories
- NuVasive Inc.
- Orthofix Medical Inc.
- Biobank
- Stryker
- TBF
- Geistlich Pharma AG
- DePuy Synthes (Johnson & Johnson)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.82 Billion |
| Forecasted Market Value ( USD | $ 7.53 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
